Male New Zealand white rabbits (n=32; aged 12 weeks) were used in the experiments. Animals were housed in separate metal cages at a temperature of 23°C±2°C and relative humidity of 45%±10%. The animals were allowed free access to tap water and were fed a commercial rabbit diet. Animal experiments were performed in accordance with internationally accredited guidelines and approved by laboratory’s Institutional Animal Care and Use Committee.
In laboratory tests on fat cells from rodents, pigs, dogs, and humans, the HGH fragment released fat specifically from obese fat cells but not from lean ones, reduced new fat accumulation in all fat cells, enhanced the burning of fat. In rodents (rats and mice), HGH fragment reduced body fat in obese animals but, enhanced fat burning without changing food consumption or inducing growth (as it does not increase IGF levels) or any other unwanted Growth Hormone effect. Recent research has shown AOD9604 to be an extremely potent and effective fat burner. Metabolic is developing AOD-9604 for the potential treatment of obesity. Research studies have shown that AOD9604 actually acts on the reduction of excessive adipose tissues such as those in the abdominal area, increase in muscle mass, and enhances the lipid content of the body.
Peptides are defined as a compound of two or more amino acids in which a carboxyl group of one is united with an amino group of another. With the elimination of a water molecule, a peptide bond is formed. To put it more simply, peptides are just small proteins. When the number of amino acids are less than 50, these are peptides. When higher than 50, these are proteins. The peptides are therefore small chains of amino acid which are present in all cells of the body. There are several kinds of peptides: oligopeptides, polymers, proteins, neuropeptides and peptide hormones. These are synthesized naturally by the body. Peptides will therefore be used primarily to make a more abundant amount of hormones in the body. The latter will then produce new hormones such as Testosterone or corticosteroids. It is these two hormones that are considered anabolic or indirect anti-inflammatory.

The medicines delegate referred the proposal to upschedule paracetamol/ibuprofen from Schedule 2 to Schedule 3 to the Advisory Committee on Medicines Scheduling (ACMS) in early 2011. The proposal was submitted by the Advisory Committee on Non-Prescription Medicines (ACNM) as they were currently assessing a product in which the sponsor did not satisfactorily establish the efficacy and safety of the product and that public health concerns raised during the assessment of the product could be addressed by access to a pharmacist. AFT Pharmaceuticals had submitted a product application with the TGA at the time of this item being considered by the delegate and ACMS.
The mean time (± SD) taken for recovery of normal ambulation was 25±2 days in Group 1, 15±3 days in Group 2, 16±2 days in Group 3, and 11±4 days in Group 4. The lameness period in Group 4 was significantly shorter than those in Groups 1, 2, and 3 (p<0.05). The lameness period in Group 1 was significantly longer than those in Groups 2 and 3 (p<0.05). However, there were no differences in the mean lameness period between Groups 2 and 3 (Figure 6).
AOD9604, a synthetic fragment of hGH consisting of the amino acid residues 177–191 with the addition of a tyrosine residue to the N-terminus was prepared with solid-phase synthesis procedure and purified with reverse-phase HPLC methodology in our laboratories (13). The structure of the peptide analog was verified with mass spectrometry and amino acid analysis. The hGH was a gift of Professor Michael Waters (University of Queensland, Brisbane, Australia). BRL37344 (β3-AR agonist) was a gift from Dr. Jon Arch (SmithKline Beecham, Harlow, UK).
There were concerns regarding the number of contraindications and precautions and whether consumers would be able to interpret these appropriately without a requirement for pharmacist advice. There were concerns regarding gastro-intestinal, renal and other adverse effects related to the potential interactions of ibuprofen and paracetamol. Also raised were concerns regarding the potential for paracetamol overdose.
Increasing HGH release levels in your body naturally. It sounds too good to be true, but what if you could achieve just that by using a supplement? Using Ipamorelin alongside your exercise and diet regimen is going to help you achieve said goal. No two users are alike. For athletes or those who workout religiously, you might experience greater results than an individual who is overweight and just getting back into the gym after 10 years. So, take it with a grain of salt when detailing the results below. Dosage, your body composition, and other factors will play a role in the results you can expect to see when you incorporate Ipamorelin.
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used in the management of mild to moderate pain and inflammation in conditions such as dysmenorrhoea, headache including migraine, post-operative pain, dental pain, musculoskeletal and joint disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile idiopathic arthritis, peri-articular disorders such as bursitis and tenosynovitis, and soft tissue disorders such as sprains and strains. It is also used to reduce fever.
Figure 2A shows that neither hGH nor AOD9604 had any significant effect on the weight of epididymal adipose tissue in the lean mice. However, in the ob/ob mice, AOD9604 induced a 28% decrease in epididymal adipose tissue mass, and hGH induced a 40% reduction in epididymal adipose tissue mass (P < 0.05). Brown adipose tissue weights were also measured (Fig. 2B). In this tissue, both AOD9604 and hGH induced a reduction in the weight of brown adipose tissue in both the lean and ob/ob mice.

The increase in GH secretion due to IPAMORELIN (and other GHRP) leads to an increase in IGF-1 (thought to be the anabolic mechanism of GH).  As we get older GH and subsequently IGF-1 decrease substantially.  This decline is thought to be one of the major causes of the ageing process.  By increasing these levels again there is increased collagen synthesis, promotion of lean muscle mass, bone strength, improved healing capability, improved sleep cycle, increased energy, repair and regeneration of internal organs, strengthening of joints/cartilage/connective tissue, and anti ageing effects on the skin. 

In order to demonstrate safety, several human studies were performed with AOD9604 (supplementary data): 1). METAOD001: A Phase I (double-blind, placebo-controlled, dose escalation) safety study with doses (ranging from 25 to 400 µg/kg AOD9604) administered intravenously to 15 healthy adult male volunteers presenting with a BMI between 24 and 30 kg/m2. A single dose of recombinant hGH (0.12 international units/kg) was administered intravenously as positive control. 2). METAOD002: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (25, 50 and 100 µg/kg AOD9604) administered intravenously to 23 healthy clinically obese males presenting with a BMI ≥ 35 kg/m2. 3). METAOD003: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (9, 27 and 54 mg AOD9604) administered orally (capsules) to 17 healthy, clinically obese males presenting with a BMI ≥ 35 kg/m2. 4). METAOD004: A Phase IIa (double-blind, placebo-controlled, dose escalation) safety study with multiple daily doses (9, 27 or 54 mg AOD9604) administered orally (capsules) for seven days in 36 healthy clinically obese males presenting with a BMI ≥ 30 kg/m2. 5). METAOD005: A Phase IIb (randomized, double-blind, placebo-controlled) study to assess the efficacy (reduction in body weight), safety and tolerability of 12 weeks treatment with daily doses (1, 5, 10, 20 or 30 mg AOD9604) administered orally (capsules) in 300 healthy, clinically obese males, and females of non-child bearing potential, with a BMI ≥ 35 kg/m2. 6). METAOD006: A Phase IIb, randomized, double-blind, placebo-controlled study to assess the efficacy (reduction in body weight), safety and tolerability of 24 weeks treatment with different doses of AOD9604 tablets (0.25 mg, 0.5 mg, 1 mg, or placebo) in 502 obese adults.


To buy our premium peptides online you will need to complete a simple online medical questionnaire. This is a legal requirement due to the regulation of Peptides in Australia. We cannot legally advertise specific Peptides to the general public without first ascertaining you are over 18 years of age and have submitted the required medical questionnaire. Learn more about Muscle Peptides Australia services.
×